Is CNTB or CABA more profitable?

Connect Biopharma's return on equity of -122.29% beat Cabaletta Bio's return on equity. Company Net Margins Return on Equity Return on Assets Connect Biopharma N/A -122.29% -97.07% Cabaletta Bio N/A -131.58% -96.46%

Does the media refer more to CNTB or CABA?

In the previous week, Cabaletta Bio had 3 more articles in the media than Connect Biopharma. MarketBeat recorded 5 mentions for Cabaletta Bio and 2 mentions for Connect Biopharma. Connect Biopharma's average media sentiment score of 1.92 beat Cabaletta Bio's score of 0.10 indicating that Connect Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Connect Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Cabaletta Bio 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CTMX or CNTB?

In the previous week, CytomX Therapeutics had 1 more articles in the media than Connect Biopharma. MarketBeat recorded 3 mentions for CytomX Therapeutics and 2 mentions for Connect Biopharma. Connect Biopharma's average media sentiment score of 1.92 beat CytomX Therapeutics' score of 0.00 indicating that Connect Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Connect Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to DNA or CNTB?

In the previous week, Connect Biopharma had 1 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 2 mentions for Connect Biopharma and 1 mentions for Ginkgo Bioworks. Connect Biopharma's average media sentiment score of 1.92 beat Ginkgo Bioworks' score of 1.65 indicating that Connect Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ginkgo Bioworks 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Connect Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts rate CNTB or AVTE?

Connect Biopharma presently has a consensus price target of $7.20, suggesting a potential upside of 228.77%. Given Connect Biopharma's stronger consensus rating and higher probable upside, research analysts plainly believe Connect Biopharma is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Connect Biopharma 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86 Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is CNTB or AVTE more profitable?

Aerovate Therapeutics' return on equity of -90.19% beat Connect Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Connect Biopharma N/A -122.29% -97.07% Aerovate Therapeutics N/A -90.19% -77.47%

Is CADL or CNTB more profitable?

Candel Therapeutics' return on equity of -60.42% beat Connect Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Candel Therapeutics N/A -60.42% -41.33% Connect Biopharma N/A -122.29% -97.07%

Does the media prefer CADL or CNTB?

In the previous week, Candel Therapeutics had 3 more articles in the media than Connect Biopharma. MarketBeat recorded 5 mentions for Candel Therapeutics and 2 mentions for Connect Biopharma. Connect Biopharma's average media sentiment score of 1.92 beat Candel Therapeutics' score of 0.52 indicating that Connect Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Candel Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Connect Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Connect Biopharma (CNTB) Competitors

$2.19 +0.02 (+0.92%)

As of 01:07 PM Eastern

Compare

CNTB vs. CABA, CTMX, DNA, AVTE, and CADL

Should you buy Connect Biopharma stock or one of its competitors? MarketBeat compares Connect Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Connect Biopharma include Cabaletta Bio (CABA), CytomX Therapeutics (CTMX), Ginkgo Bioworks (DNA), Aerovate Therapeutics (AVTE), and Candel Therapeutics (CADL). These companies are all part of the "pharmaceutical products" industry.

How does Connect Biopharma compare to Cabaletta Bio?

Connect Biopharma (NASDAQ:CNTB) and Cabaletta Bio (NASDAQ:CABA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability.

Connect Biopharma presently has a consensus target price of $7.20, indicating a potential upside of 228.77%. Cabaletta Bio has a consensus target price of $15.50, indicating a potential upside of 386.66%. Given Cabaletta Bio's higher probable upside, analysts clearly believe Cabaletta Bio is more favorable than Connect Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Connect Biopharma has higher revenue and earnings than Cabaletta Bio. Connect Biopharma is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Connect Biopharma	$233K	591.81	-$55.48M	-$1.15	N/A
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.96	N/A

In the previous week, Cabaletta Bio had 3 more articles in the media than Connect Biopharma. MarketBeat recorded 5 mentions for Cabaletta Bio and 2 mentions for Connect Biopharma. Connect Biopharma's average media sentiment score of 1.92 beat Cabaletta Bio's score of 0.10 indicating that Connect Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Connect Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Cabaletta Bio	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Connect Biopharma's return on equity of -122.29% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Connect Biopharma	N/A	-122.29%	-97.07%
Cabaletta Bio	N/A	-131.58%	-96.46%

Connect Biopharma has a beta of -0.22, indicating that its share price is 122% less volatile than the broader market. Comparatively, Cabaletta Bio has a beta of 3.21, indicating that its share price is 221% more volatile than the broader market.

58.7% of Connect Biopharma shares are held by institutional investors. 22.6% of Connect Biopharma shares are held by insiders. Comparatively, 6.4% of Cabaletta Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Connect Biopharma beats Cabaletta Bio on 9 of the 14 factors compared between the two stocks.

How does Connect Biopharma compare to CytomX Therapeutics?

CytomX Therapeutics (NASDAQ:CTMX) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

CytomX Therapeutics currently has a consensus price target of $12.10, suggesting a potential upside of 311.42%. Connect Biopharma has a consensus price target of $7.20, suggesting a potential upside of 228.77%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe CytomX Therapeutics is more favorable than Connect Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

CytomX Therapeutics has higher revenue and earnings than Connect Biopharma. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$35.54M	14.08	-$17.37M	-$0.41	N/A
Connect Biopharma	$233K	591.81	-$55.48M	-$1.15	N/A

In the previous week, CytomX Therapeutics had 1 more articles in the media than Connect Biopharma. MarketBeat recorded 3 mentions for CytomX Therapeutics and 2 mentions for Connect Biopharma. Connect Biopharma's average media sentiment score of 1.92 beat CytomX Therapeutics' score of 0.00 indicating that Connect Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytomX Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Connect Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

CytomX Therapeutics has a beta of 2.08, suggesting that its stock price is 108% more volatile than the broader market. Comparatively, Connect Biopharma has a beta of -0.22, suggesting that its stock price is 122% less volatile than the broader market.

Connect Biopharma has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -166.40%. CytomX Therapeutics' return on equity of -36.61% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-166.40%	-36.61%	-28.02%
Connect Biopharma	N/A	-122.29%	-97.07%

67.8% of CytomX Therapeutics shares are owned by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are owned by institutional investors. 6.6% of CytomX Therapeutics shares are owned by insiders. Comparatively, 22.6% of Connect Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

CytomX Therapeutics beats Connect Biopharma on 11 of the 16 factors compared between the two stocks.

How does Connect Biopharma compare to Ginkgo Bioworks?

Ginkgo Bioworks (NYSE:DNA) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, analyst recommendations and dividends.

Ginkgo Bioworks has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market. Comparatively, Connect Biopharma has a beta of -0.22, suggesting that its stock price is 122% less volatile than the broader market.

Connect Biopharma has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -215.41%. Ginkgo Bioworks' return on equity of -56.08% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-215.41%	-56.08%	-26.06%
Connect Biopharma	N/A	-122.29%	-97.07%

Connect Biopharma has lower revenue, but higher earnings than Ginkgo Bioworks. Connect Biopharma is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$151.40M	3.52	-$312.76M	-$5.36	N/A
Connect Biopharma	$233K	591.81	-$55.48M	-$1.15	N/A

In the previous week, Connect Biopharma had 1 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 2 mentions for Connect Biopharma and 1 mentions for Ginkgo Bioworks. Connect Biopharma's average media sentiment score of 1.92 beat Ginkgo Bioworks' score of 1.65 indicating that Connect Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ginkgo Bioworks	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Connect Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Ginkgo Bioworks presently has a consensus target price of $8.50, suggesting a potential upside of 4.15%. Connect Biopharma has a consensus target price of $7.20, suggesting a potential upside of 228.77%. Given Connect Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Connect Biopharma is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

78.6% of Ginkgo Bioworks shares are held by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are held by institutional investors. 12.7% of Ginkgo Bioworks shares are held by company insiders. Comparatively, 22.6% of Connect Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Connect Biopharma beats Ginkgo Bioworks on 11 of the 17 factors compared between the two stocks.

How does Connect Biopharma compare to Aerovate Therapeutics?

Connect Biopharma (NASDAQ:CNTB) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Connect Biopharma has a beta of -0.22, indicating that its share price is 122% less volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market.

Connect Biopharma has higher revenue and earnings than Aerovate Therapeutics. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Connect Biopharma	$233K	591.81	-$55.48M	-$1.15	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

Aerovate Therapeutics' return on equity of -90.19% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Connect Biopharma	N/A	-122.29%	-97.07%
Aerovate Therapeutics	N/A	-90.19%	-77.47%

58.7% of Connect Biopharma shares are held by institutional investors. 22.6% of Connect Biopharma shares are held by company insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Connect Biopharma had 2 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 2 mentions for Connect Biopharma and 0 mentions for Aerovate Therapeutics. Connect Biopharma's average media sentiment score of 1.92 beat Aerovate Therapeutics' score of 0.00 indicating that Connect Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Connect Biopharma	Very Positive
Aerovate Therapeutics	Neutral

Connect Biopharma presently has a consensus price target of $7.20, suggesting a potential upside of 228.77%. Given Connect Biopharma's stronger consensus rating and higher probable upside, research analysts plainly believe Connect Biopharma is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Connect Biopharma beats Aerovate Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Connect Biopharma compare to Candel Therapeutics?

Candel Therapeutics (NASDAQ:CADL) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations.

13.9% of Candel Therapeutics shares are held by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are held by institutional investors. 14.3% of Candel Therapeutics shares are held by company insiders. Comparatively, 22.6% of Connect Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Candel Therapeutics has a beta of -0.49, suggesting that its share price is 149% less volatile than the broader market. Comparatively, Connect Biopharma has a beta of -0.22, suggesting that its share price is 122% less volatile than the broader market.

Candel Therapeutics' return on equity of -60.42% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-60.42%	-41.33%
Connect Biopharma	N/A	-122.29%	-97.07%

In the previous week, Candel Therapeutics had 3 more articles in the media than Connect Biopharma. MarketBeat recorded 5 mentions for Candel Therapeutics and 2 mentions for Connect Biopharma. Connect Biopharma's average media sentiment score of 1.92 beat Candel Therapeutics' score of 0.52 indicating that Connect Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Candel Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Connect Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Candel Therapeutics currently has a consensus target price of $18.00, suggesting a potential upside of 111.64%. Connect Biopharma has a consensus target price of $7.20, suggesting a potential upside of 228.77%. Given Connect Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Connect Biopharma is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Candel Therapeutics has higher earnings, but lower revenue than Connect Biopharma. Candel Therapeutics is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A
Connect Biopharma	$233K	591.81	-$55.48M	-$1.15	N/A

Summary

Connect Biopharma beats Candel Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Connect Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNTB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CNTB vs. The Competition

Export

Metric	Connect Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$137.89M	$3.30B	$6.45B	$12.12B
Dividend Yield	N/A	2.31%	2.67%	5.56%
P/E Ratio	-1.90	19.15	23.92	23.81
Price / Sales	591.81	176.25	480.90	87.50
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	2.92	8.03	10.36	6.75
Net Income	-$55.48M	$23.89M	$3.57B	$337.72M
7 Day Performance	-6.41%	-5.75%	-1.11%	-3.06%
1 Month Performance	-7.20%	2.11%	3.40%	1.59%
1 Year Performance	176.69%	36.67%	23.87%	27.17%

Connect Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CNTB Connect Biopharma	3.9548 of 5 stars	$2.19 +0.9%	$7.20 +228.8%	+174.2%	$137.89M	$233K	N/A	110
CABA Cabaletta Bio	2.9427 of 5 stars	$3.67 -2.9%	$15.50 +322.3%	+31.0%	$616.35M	N/A	N/A	50	News Coverage
CTMX CytomX Therapeutics	2.1417 of 5 stars	$3.45 -4.2%	$12.10 +250.7%	+13.6%	$612.67M	$35.54M	N/A	170	High Trading Volume
DNA Ginkgo Bioworks	1.7475 of 5 stars	$9.14 -2.5%	$8.50 -7.0%	+7.9%	$612.09M	$170.15M	N/A	640	Positive News Gap Up
AVTE Aerovate Therapeutics	N/A	$21.04 +1.0%	N/A	+135.6%	$609.84M	N/A	N/A	20	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CNTB) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Connect Biopharma (CNTB) Competitors

CNTB vs. CABA, CTMX, DNA, AVTE, and CADL

How does Connect Biopharma compare to Cabaletta Bio?

Summary

How does Connect Biopharma compare to CytomX Therapeutics?

Summary

How does Connect Biopharma compare to Ginkgo Bioworks?

Summary

How does Connect Biopharma compare to Aerovate Therapeutics?

Summary

How does Connect Biopharma compare to Candel Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTB vs. The Competition

Connect Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Connect Biopharma (CNTB) Competitors

CNTB vs. CABA, CTMX, DNA, AVTE, and CADL

How does Connect Biopharma compare to Cabaletta Bio?

Do analysts rate CNTB or CABA?

Which has better valuation and earnings, CNTB or CABA?

Does the media refer more to CNTB or CABA?

Is CNTB or CABA more profitable?

Which has more volatility & risk, CNTB or CABA?

Do insiders & institutionals believe in CNTB or CABA?

Summary

How does Connect Biopharma compare to CytomX Therapeutics?

Do analysts rate CTMX or CNTB?

Which has better valuation & earnings, CTMX or CNTB?

Does the media favor CTMX or CNTB?

Which has more risk and volatility, CTMX or CNTB?

Is CTMX or CNTB more profitable?

Do insiders and institutionals hold more shares of CTMX or CNTB?

Summary

How does Connect Biopharma compare to Ginkgo Bioworks?

Which has more risk and volatility, DNA or CNTB?

Is DNA or CNTB more profitable?

Which has better valuation and earnings, DNA or CNTB?

Does the media refer more to DNA or CNTB?

Do analysts rate DNA or CNTB?

Do institutionals and insiders have more ownership in DNA or CNTB?

Summary

How does Connect Biopharma compare to Aerovate Therapeutics?

Which has more risk & volatility, CNTB or AVTE?

Which has higher valuation & earnings, CNTB or AVTE?

Is CNTB or AVTE more profitable?

Do institutionals and insiders hold more shares of CNTB or AVTE?

Does the media prefer CNTB or AVTE?

Do analysts rate CNTB or AVTE?

Summary

How does Connect Biopharma compare to Candel Therapeutics?

Do insiders & institutionals believe in CADL or CNTB?

Which has more volatility and risk, CADL or CNTB?

Is CADL or CNTB more profitable?

Does the media prefer CADL or CNTB?

Do analysts rate CADL or CNTB?

Which has higher valuation and earnings, CADL or CNTB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTB vs. The Competition

Connect Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools